{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:57:08Z","timestamp":1775480228955,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,6]]},"DOI":"10.7759\/cureus.106515","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:11:12Z","timestamp":1775477472000},"source":"Crossref","is-referenced-by-count":0,"title":["Hemorrhagic Ascites in Chronic Lymphocytic Leukemia With Immunoglobulin Heavy Chain Variable Region 3-21 (IGHV3-21) Usage: A Case Requiring Individualized Treatment"],"prefix":"10.7759","author":[{"given":"Suhail","family":"Sapkota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niket","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Bayya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasneet","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreebridhi","family":"Pande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Motkur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Sushrutha","family":"Mudupula Vemula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borys","family":"Hrinczenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek M","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al.. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008, 111:5446-56. 10.1182\/blood-2007-06-093906","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek M","year":"2019","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019, 94:1266-87. 10.1002\/ajh.25595","journal-title":"Am J Hematol"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle RN","year":"1999","unstructured":"Damle RN, Wasil T, Fais F, et al.. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999, 94:1840-7.","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600874","article-title":"Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations","volume":"125","author":"Baliakas P","year":"2015","unstructured":"Baliakas P, Agathangelidis A, Hadzidimitriou A, et al.. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015, 125:856-9. 10.1182\/blood-2014-09-600874","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos K","year":"2007","unstructured":"Stamatopoulos K, Belessi C, Moreno C, et al.. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007, 109:259-70. 10.1182\/blood-2006-03-012948","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.3594","article-title":"Massive ascites as a presenting manifestation of chronic lymphocytic leukemia","volume":"14","author":"Siddiqui N","year":"2008","unstructured":"Siddiqui N, Al-Amoudi S, Aleem A, Arafah M, Al-Gwaiz L. Massive ascites as a presenting manifestation of chronic lymphocytic leukemia. World J Gastroenterol. 2008, 14:3594-7. 10.3748\/wjg.14.3594","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2044","article-title":"Chronic lymphocytic leukemia presenting with ascites diagnosed by clonality analysis via gene rearrangement assay: a case report","volume":"7","author":"Huang YM","year":"2014","unstructured":"Huang YM, Shih LY, Dunn P, et al.. Chronic lymphocytic leukemia presenting with ascites diagnosed by clonality analysis via gene rearrangement assay: a case report. Oncol Lett. 2014, 7:1911-4. 10.3892\/ol.2014.2044","journal-title":"Oncol Lett"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007039","article-title":"Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL","volume":"137","author":"Agathangelidis A","year":"2021","unstructured":"Agathangelidis A, Chatzidimitriou A, Gemenetzi K, et al.. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood. 2021, 137:1365-76. 10.1182\/blood.2020007039","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown JR","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W, et al.. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025, 392:748-62. 10.1056\/NEJMoa2409804","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716681749","article-title":"The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies","volume":"8","author":"Skarbnik AP","year":"2017","unstructured":"Skarbnik AP, Faderl S. The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies. Ther Adv Hematol. 2017, 8:99-105. 10.1177\/2040620716681749","journal-title":"Ther Adv Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/452329-hemorrhagic-ascites-in-chronic-lymphocytic-leukemia-with-immunoglobulin-heavy-chain-variable-region-3-21-ighv3-21-usage-a-case-requiring-individualized-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:11:13Z","timestamp":1775477473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/452329-hemorrhagic-ascites-in-chronic-lymphocytic-leukemia-with-immunoglobulin-heavy-chain-variable-region-3-21-ighv3-21-usage-a-case-requiring-individualized-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.106515","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}